ClinicalTrials.gg
Not yet recruitingNCT07719023Updated Jul 22, 2026

A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

A Phase 3 interventional study of AK3280 and Placebo in Idiopathic Pulmonary Fibrosis (IPF), sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
263
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Planned enrollment
20th of 60
263 · median 83
Started
2026
with 12 others
Phase 3
13 of 67
5 open now
Primary completion
2028-09
later than 19 of 28 live
Registered
63rd of 67
by date

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 20th largest by planned enrollment of the 60 interventional ones that give a count, is one of 13 that started in 2026, is one of 13 in phase 3, reaches primary completion later than 19 of the 28 other live ones, and was the 63rd registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

This is a phase 3 clinical study conducted in China. The primary objective is to compare the efficacy and safety of AK3280 400 mg versus placebo and active control (pirfenidone) in IPF patients.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled and open-label active-controlled phase 3 clinical study conducted in China. This study plans to enroll 263 IPF participants. After completing screening assessments and meeting all enrollment criteria, IPF participants will be randomized in a 4:2:1 ratio to: AK3280 400 mg BID group (double-blind); Placebo BID group (double-blind); Pirfenidone 600 mg TID group (open-label).

The doctors regularly test participants' lung function. The results of the lung function tests are compared between the groups. The doctors also regularly check participants' health and record any adverse medical events.

Participants are in the study for up to one and a half years. Subjects who complete the Week 52 visit of randomized controlled treatment study may be offered the opportunity to enter an open-label extension (OLE) study.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis (IPF)

Keywords

  • AK3280
  • IPF
  • Pirfenidone
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 40 years at enrolment
  2. Diagnosis of IPF per ATS/ERS/JRS/ALAT 2022 guidelines
  3. HRCT central review completed during screening or within 12 months prior to screening. If participant did not undergo lung surgical , HRCT imaging must be consistent with usual interstitial pneumonia (UIP) pattern for definitive IPF diagnosis.
  4. No prior anti-fibrotic treatment, or discontinued anti-fibrotic therapy for ≥4 weeks or 5 half-lives (whichever is longer) prior to randomization
  5. Screening assessments meeting all of the following: 1) Standardized %pFVC ≥ 50% and ≤ 90%;2) -corrected %pDLco ≥ 30% and ≤ 90%;3) Resting SpO2 ≥ 88%

Exclusion criteria

Exclusion Criteria:

  1. History of to pirfenidone or AK3280
  2. Known intolerance to pirfenidone single dose of 200 mg (total daily dose 600 mg)
  3. Hospitalization due to acute IPF exacerbation within 8 weeks prior to screening or during screening
  4. Within 4 weeks prior to screening or during screening, local or systemic infection requiring: 1) Hospitalization ≥ 24 hours; or 2) Use of systemic antibiotics (IV, IM, oral, or inhaled)
  5. History of active tuberculosis within 12 months prior to screening
  6. History of other lung diseases besides IPF (e.g., asthma, , interstitial pneumonia of known cause, acute severe pulmonary infection, etc.), or planned lung transplantation within 6 months after signing
  7. Post-bronchodilator /FVC \< 0.7 or positive bronchodilator response (defined as ≥ 12% relative increase in FEV1 and ≥ 200 mL absolute increase in FEV1 after bronchodilator use) during screening
  8. History of heart disease meeting Class III-IV
  9. History of liver cirrhosis, severe hepatic impairment, or end-stage liver disease
  10. Screening liver function abnormalities meeting any of the following:1) ≥ 2× ; 2) ALT ≥ 2× ULN; 3) ALP ≥ 2× ULN; 4) Total ≥ 1.5× ULN
  11. Screening cystatin C-estimated \< 60 mL/min/1.73m²
  12. Screening coagulation test meeting any of the following: 1) > 2; 2) Both PT and APTT prolonged > 1.5× ULN
  13. History of any clinically diagnosed disease, including but not limited to scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis
  14. Uncontrolled diabetes during screening ( > 10%)
  15. History of or possible malignancy upon evaluation (except treated localized basal cell carcinoma of the skin or cervical carcinoma in situ without recurrence)
  16. History of immunodeficiency, including but not limited to infection
  17. History of any disease other than IPF with \< 18 months; or requiring long-term medical care, or limited self-care ability; or conditions that the investigator believes may affect participant's ability to complete this clinical study, complete study-related assessments, or affect safety or efficacy assessments
  18. Use of prohibited medications with potential effects on efficacy endpoints within 4 weeks or 5 half-lives (whichever is longer) prior to randomization
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
263 participants (estimated)

Study arms

  • Experimental
    AK3280 400 mg BID

    During the randomized controlled treatment study, participants will receive AK3280 400 mg twice daily in a masked manner.

    Drug: AK3280

  • Placebo comparator
    Placebo

    During the randomized controlled treatment study, participants will receive placebo matching 400 mg twice daily in a masked manner.

    Drug: Placebo

  • Active comparator
    Pirfenidone 600 mg TID

    During the randomized controlled treatment study, participants will receive pirfenidone titrated gradually to 600 mg three times daily in an open-label manner.

    Drug: Pirfenidone

Interventions

  • DrugAK3280

    Participants will receive AK3280 400 mg twice daily, within 30 minutes after breakfast and dinner, with breakfast and dinner approximately 12 hours apart.

  • DrugPlacebo

    Participants will receive placebo matching 400 mg twice daily, within 30 minutes after breakfast and dinner, with breakfast and dinner approximately 12 hours apart.

  • Participants will receive pirfenidone three times daily, within 30 minutes after meals. Initial dosing should be titrated gradually under doctor guidance: start with 200 mg each time, increase by 200 mg each time to maintain final dose of 600 mg each time within 2 weeks.

06

What researchers measure

Primary outcomes

  1. Absolute change from baseline in FVC at Week 52

    The FVC indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath.

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Absolute change from baseline in FVC at Week 12, 24, and 42

    The FVC indicates the amount of air a person can forcefully and quickly exhale after taking a deep breath.

    Time frame: Baseline to Week 12, 24, and 42

  2. Proportion of participants with relative decline from baseline in FVC ≥10%, ≥15%, and ≥20% at Week 12, 24, 42, and 52

    Relative decline from baseline in FVC ≥10%, ≥15%, and ≥20% indicates varying degrees of disease progression.

    Time frame: At Week 12, 24, 42, and 52

  3. Absolute change from baseline in standardized %pFVC at Week12, 24, 42, and 52

    Standardized %pFVC is calculated as the ratio of measured FVC to predicted FVC. The predicted FVC is derived using a standardized formula.

    Time frame: Baseline to Week 12, 24, 42, and 52

  4. Proportion of participants with absolute decline from baseline in standardized %pFVC ≥10% at Week 12, 24, 42, and 52

    Absolute decline from baseline in standardized %pFVC ≥10% indicates rapid disease progression.

    Time frame: At Week 12, 24, 42, and 52

  5. Absolute change from baseline in hemoglobin-corrected %pDLco at Week 12, 24, 42, and 52

    The hemoglobin-corrected %pDLco measures the ability of oxygen moves from alveoli to blood.

    Time frame: At Week 12, 24, 42, and 52

  6. Change from baseline in L-PF score at Week 12, 24, 42, and 52

    The L-PF is a self-administered, quality of life questionnaire validated for patients with progressive fibrosing interstitial lung disease (ILD), including IPF.

    Time frame: At Week 12, 24, 42, and 52

  7. Change from baseline in 6MWT distance at Week 12, 24, 42, and 52

    Time frame: At Week 12, 24, 42, and 52

  8. Time to first acute exacerbation of IPF within 52 weeks

    An exacerbation of IPF is defined as an acute, clinically significant, respiratory deterioration characterized by evidence of new widespread alveolar abnormality in HRCT.

    Time frame: Baseline to Week 52

  9. Progression-free survival (PFS), defined as the time from randomization to disease progression or death, whichever occurs first.

    IPF disease progression is defined as the occurrence of any of the following events: 1. ≥ 10% absolute decline from baseline in standardized %pFVC 2. ≥ 15% absolute decline from baseline in hemoglobin-corrected %pDLco 3. Unscheduled hospitalization due to respiratory events

    Time frame: Baseline to Week 52

  10. Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) within 52 weeks

    TEAEs and SAEs will be assessed via patient-reported symptoms, vital signs, physical examination, 12-lead ECG, HRCT, and laboratory assessments.

    Time frame: Baseline to Week 52

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Sep 2028, 24 months later.

Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 22, 2026
StartEst.
Aug 31, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Mar 31, 2029
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07719023
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Aug 31, 2026 (estimated)
Primary completion
Sep 30, 2028 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Jul 22, 2026

Study contacts

Jayson Zhou
Contact
jayson.zhou@arkbiosciences.com
+8618796252099
Zhen Fu, Medical Director
study director

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AK3280

Start the discussion